CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
CVRX Chart
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone, and welcome to today's CVRx Q1 2025 earnings call. At this time, all participants are in a listen-only mode.
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago.
CVRx, Inc. Dividends
CVRx, Inc. Earnings
| 28 Jul 2025 (36 Days) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 23 Jan 2025 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 24 Oct 2024 Date | | - Cons. EPS | - EPS |
| 28 Jul 2025 (36 Days) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 23 Jan 2025 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 24 Oct 2024 Date | | - Cons. EPS | - EPS |
CVRx, Inc. (CVRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has CVRx, Inc. ever had a stock split?
CVRx, Inc. Profile
| Medical - Devices Industry | Healthcare Sector | Mr. Kevin Hykes CEO | NASDAQ (NGS) Exchange | 126638105 Cusip |
| US Country | 206 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CVRx, Inc. is a commercial-stage medical device company with a primary focus on the development, manufacturing, and commercialization of neuromodulation solutions aimed at treating cardiovascular diseases. Incorporated in the year 2000 and based in Minneapolis, Minnesota, CVRx has positioned itself at the forefront of the medical device industry by targeting a significant need within the cardiovascular disease treatment spectrum. Through its innovative approach, the company seeks to improve the quality of life for patients suffering from severe cardiovascular conditions by leveraging the potential of neuromodulation therapies. CVRx not only serves patients within the United States but also reaches a global audience, including Germany, through a combination of direct sales force, sales agents, and independent distributors, underscoring its commitment to addressing heart failure on a worldwide scale.
Products and Services
- Barostim
Barostim stands out as CVRx, Inc.’s flagship neuromodulation device, designed specifically to offer symptom improvement for patients dealing with heart failure with reduced ejection fraction, commonly referred to as systolic heart failure. By leveraging the advanced mechanism of neuromodulation, Barostim aims at enhancing the quality of life for those afflicted by this debilitating condition, marking a significant milestone in the treatment of heart failure. Its indication for this particular group of patients highlights the company's dedication to filling a critical gap in cardiovascular disease management through innovative technology.
Contact Information
